The King’s College London radiopharma spinout will combine detection with treatment to target hard-to-treat cancer cells ...
King's biotech spin-out to identify and target therapy-resistant cancers. King's spin-out company Nuclide Therapeutics (NTx ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback